Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for acute antibody-mediated rejection in kidney transplant
NCT03994783Phase 3Terminated
- Sponsor
- Imperial College London
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in kidney transplant rejection, sponsored by Imperial College London. Started Jul 2019; status: terminated.
02
Drugs
rituximab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03994783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994783.